Study S002408

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study of Oral RGT001-075 in Adult Patients With Uncontrollable Type 2 Diabetes Mellitus on Metformin Therapy

ClinicalTrials.gov record

Registration

Registration: NCT05297045
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: TERMINATED
Enrollment: 17
Start: 2022-03-29
Primary completion: 2023-05-30
Lead sponsor: Regor Pharmaceuticals Inc.
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:RGT001-075; OTHER:Placebo
Results posted: FALSE

Registered primary outcomes

Change in HbA1c from baseline to end of treatment in the modified intent-to-treat population [up to 16 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.